These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 6989479)

  • 21. In situ clinical effects of new dentifrices containing 1.5% arginine and fluoride on enamel de- and remineralization and plaque metabolism.
    Cantore R; Petrou I; Lavender S; Santarpia P; Liu Z; Gittins E; Vandeven M; Cummins D; Sullivan R; Utgikar N
    J Clin Dent; 2013; 24 Spec no A():A32-44. PubMed ID: 24156138
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of the effects on dentin permeability of two commercially available sensitivity relief dentifrices.
    Patel R; Chopra S; Vandeven M; Cummins D
    J Clin Dent; 2011; 22(4):108-12. PubMed ID: 22403986
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Our experience in the treatment of post-menopausal osteoporosis (author's transl)].
    Rico Lenza H; Espinós Pérez D
    Med Clin (Barc); 1982 Apr; 78(8):322-5. PubMed ID: 7087600
    [No Abstract]   [Full Text] [Related]  

  • 24. [Comparison of the therapeutic effect on skeletal fluorosis and impact on urine fluoride value among fire needle therapy, electroacupuncture and calcium carbonate D3].
    Wang T; Yang XG; Wu ZC; Zhou JC; Chen ZJ; Hu J; Jiao Y; Zhao XG
    Zhongguo Zhen Jiu; 2014 Mar; 34(3):213-7. PubMed ID: 24843955
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Multidisciplinary study of the prolonged treatment of involution osteoporosis using sodium fluoride with calcium, phosphate and vitamin D].
    Courvoisier B; Baud CA; Véry JM; Assimacopoulos A; Tochon-Danguy HJ; Boivin G; Donath A; Garcia J; Gasser A; Fischer J
    Schweiz Med Wochenschr; 1985 Jul; 115(27-28):922-31. PubMed ID: 4023678
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Improvement of MBD parameters in dialysis patients by a switch to, and combined use of lanthanum carbonate: Josai Dialysis Forum collaborative study.
    Shinoda T; Yamasaki M; Chida Y; Takagi M; Tanaka Y; Ando R; Suzuki T; Tagawa H
    Ther Apher Dial; 2013 Apr; 17 Suppl 1():29-34. PubMed ID: 23586510
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intestinal absorption of fluoride preparations.
    Deka RC; Kacker SK; Shambaugh GE
    Laryngoscope; 1978 Dec; 88(12):1918-21. PubMed ID: 732493
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of bone weakness in patients with femoral neck fracture by fluoride, calcium and vitamin D.
    Mackie IG; Ralis ZA; Leyshon RL; Lane J; Watkins G; Berry PF
    J Bone Joint Surg Br; 1989 Jan; 71(1):111-7. PubMed ID: 2914978
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fluoride bioavailability from immediate-release sodium fluoride with calcium carbonate compared with slow-release sodium fluoride with calcium citrate.
    Sakhaee K; Pak CY
    Bone Miner; 1991 Aug; 14(2):131-6. PubMed ID: 1912761
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fluoride salts are no better at preventing new vertebral fractures than calcium-vitamin D in postmenopausal osteoporosis: the FAVOStudy.
    Meunier PJ; Sebert JL; Reginster JY; Briancon D; Appelboom T; Netter P; Loeb G; Rouillon A; Barry S; Evreux JC; Avouac B; Marchandise X
    Osteoporos Int; 1998; 8(1):4-12. PubMed ID: 9692071
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk-benefit ratio of sodium fluoride treatment in primary vertebral osteoporosis.
    Mamelle N; Meunier PJ; Dusan R; Guillaume M; Martin JL; Gaucher A; Prost A; Zeigler G; Netter P
    Lancet; 1988 Aug; 2(8607):361-5. PubMed ID: 2899773
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effect of sodium monofluorophosphate plus calcium on vertebral fracture rate in postmenopausal women with moderate osteoporosis. A randomized, controlled trial.
    Reginster JY; Meurmans L; Zegels B; Rovati LC; Minne HW; Giacovelli G; Taquet AN; Setnikar I; Collette J; Gosset C
    Ann Intern Med; 1998 Jul; 129(1):1-8. PubMed ID: 9652994
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Spontaneous hip fractures in fluoride-treated patients: potential causative factors.
    Gutteridge DH; Price RI; Kent GN; Prince RL; Michell PA
    J Bone Miner Res; 1990 Mar; 5 Suppl 1():S205-15. PubMed ID: 2339631
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical investigation of the anticaries efficacy of a 1.14% sodium monofluorophosphate (SMFP) calcium carbonate-based dentifrice: a two-year caries clinical trial on children in China.
    Fan X; Li X; Wan H; Hu D; Zhang YP; Volpe AR; DeVizio W
    J Clin Dent; 2008; 19(4):134-7. PubMed ID: 19278083
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Postmenopausal osteoporosis: treatment with low-dose sodium fluoride and estrogen.
    Lueg MC
    South Med J; 1988 May; 81(5):597-600. PubMed ID: 2835819
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bioavailability of calcium supplements and the effect of Vitamin D: comparisons between milk, calcium carbonate, and calcium carbonate plus vitamin D.
    Mortensen L; Charles P
    Am J Clin Nutr; 1996 Mar; 63(3):354-7. PubMed ID: 8602592
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A four-year clinical study to determine the caries-inhibiting effect of calcium glycerophosphate and sodium fluoride in calcium carbonate base dentifrices containing sodium monofluorophosphate.
    Mainwaring PJ; Naylor MN
    Caries Res; 1983; 17(3):267-76. PubMed ID: 6342787
    [No Abstract]   [Full Text] [Related]  

  • 38. Iatrogenic fluorosis.
    Grennan DM; Palmer DG; Malthus RS; Matagni MF; de Silva RT
    Aust N Z J Med; 1978 Oct; 8(5):528-31. PubMed ID: 283775
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fluoride-induced fractures: relation to osteogenic effect.
    Bayley TA; Harrison JE; Murray TM; Josse RG; Sturtridge W; Pritzker KP; Strauss A; Vieth R; Goodwin S
    J Bone Miner Res; 1990 Mar; 5 Suppl 1():S217-22. PubMed ID: 2339632
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A randomized trial of sodium fluoride (60 mg) +/- estrogen in postmenopausal osteoporotic vertebral fractures: increased vertebral fractures and peripheral bone loss with sodium fluoride; concurrent estrogen prevents peripheral loss, but not vertebral fractures.
    Gutteridge DH; Stewart GO; Prince RL; Price RI; Retallack RW; Dhaliwal SS; Stuckey BG; Drury P; Jones CE; Faulkner DL; Kent GN; Bhagat CI; Nicholson GC; Jamrozik K
    Osteoporos Int; 2002; 13(2):158-70. PubMed ID: 11908491
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.